Evidence map›Paper›PMID 30087612›Full record

ArticleFrontiers in pharmacology2018

Therapeutic Effect of Repurposed Temsirolimus in Lung Adenocarcinoma Model.

Hsuen-Wen Chang, Min-Ju Wu, Zih-Miao Lin, Chueh-Yi Wang, Shu-Yun Cheng, Yen-Kuang Lin, Yen-Hung Chow, Hui-Ju Ch'ang, Vincent H S Chang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Unlocking Novel Therapeutic Potential of Angiotensin II Receptor Blockers.International journal of molecular sciences · 2025
    Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hsuen-Wen ChangLaboratory Animal Center, Office of Research and Development, Taipei Medical University, Taipei, Taiwan.
Min-Ju WuLaboratory Animal Center, Office of Research and Development, Taipei Medical University, Taipei, Taiwan.
Zih-Miao LinThe PhD Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Chueh-Yi WangLaboratory Animal Center, Office of Research and Development, Taipei Medical University, Taipei, Taiwan.
Shu-Yun ChengLaboratory Animal Center, Office of Research and Development, Taipei Medical University, Taipei, Taiwan.
Yen-Kuang LinBiostatistics Research Center, Taipei Medical University, Taipei, Taiwan.
Yen-Hung ChowNational Institutes of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Taiwan.
Hui-Ju Ch'angNational Institute of Cancer Research, National Health Research Institutes, Zhunan, Taiwan.
Vincent H S ChangThe PhD Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is one of the major cause of cancer-related deaths worldwide. The poor prognosis and resistance to both radiation and chemotherapy urged the development of potential targets for lung cancer treatment. In this study, using a network-based cellular signature bioinformatics approach, we repurposed a clinically approved mTOR inhibitor for renal cell carcinomans, temsirolimus, as the potential therapeutic candidate for lung adenocarcinoma. The PI3K-AKT-mTOR pathway is known as one of the most frequently dysregulated pathway in cancers, including non-small-cell lung cancer. By using a well-documented lung adenocarcinoma mouse model of human pathophysiology, we examined the effect of temsirolimus on the growth of lung adenocarcinoma

Indexed as

chemotherapydrug repositioninglung adenocarcinomamTOR inhibitortemsirolimus

Identifiers

PMID30087612
PMCPMC6066584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.